- Home
- CUE vs CBAT Comparison
CUE vs CBAT Comparison
Compare CUE & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- CBAT
- Stock Information
- Founded
- CUE 2014
- CBAT 1999
- Country
- CUE United States
- CBAT China
- Employees
- CUE N/A
- CBAT N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- CBAT Industrial Machinery/Components
- Sector
- CUE Health Care
- CBAT Miscellaneous
- Exchange
- CUE Nasdaq
- CBAT Nasdaq
- Market Cap
- CUE 77.3M
- CBAT 78.7M
- IPO Year
- CUE 2018
- CBAT N/A
- Fundamental
- Price
- CUE $1.31
- CBAT $0.89
- Analyst Decision
- CUE Strong Buy
- CBAT
- Analyst Count
- CUE 5
- CBAT 0
- Target Price
- CUE $5.00
- CBAT N/A
- AVG Volume (30 Days)
- CUE 406.9K
- CBAT 1.2M
- Earning Date
- CUE 03-10-2025
- CBAT 03-14-2025
- Dividend Yield
- CUE N/A
- CBAT N/A
- EPS Growth
- CUE N/A
- CBAT N/A
- EPS
- CUE N/A
- CBAT 0.12
- Revenue
- CUE $9,532,000.00
- CBAT $207,423,403.00
- Revenue This Year
- CUE $73.11
- CBAT $0.46
- Revenue Next Year
- CUE $11.02
- CBAT $13.78
- P/E Ratio
- CUE N/A
- CBAT $7.38
- Revenue Growth
- CUE 149.53
- CBAT 2.32
- 52 Week Low
- CUE $0.45
- CBAT $0.77
- 52 Week High
- CUE $2.93
- CBAT $2.08
- Technical
- Relative Strength Index (RSI)
- CUE 52.47
- CBAT 45.53
- Support Level
- CUE $1.21
- CBAT $0.85
- Resistance Level
- CUE $1.75
- CBAT $1.11
- Average True Range (ATR)
- CUE 0.18
- CBAT 0.10
- MACD
- CUE 0.00
- CBAT -0.01
- Stochastic Oscillator
- CUE 45.00
- CBAT 10.16
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization and distribution of a variety of standard and customized lithium-ion high-power rechargeable batteries. The company operates in two operating segments: CBAK's segment mainly includes the manufacture, commercialization and distribution of a wide variety of standard and customized lithium ion rechargeable batteries for use in a wide array of applications. Hitrans' segment mainly includes the development and manufacturing of NCM precursor and cathode materials. Geographically, it generates a majority of its revenue from Mainland China and also has an operation in Europe, the United States, Korea, and Other Countries.